Xenon Pharmaceuticals develops investigational drugs for neurological and psychiatric conditions, led by azetukalner for epilepsy and depression. It last closed at $38.78 on Nov 17, down 1.22% on the day. XENE last reported earnings on Mon, Nov 9, 2026. The average 12-month price target from 7 analysts is $65.43 (+68.7% from the last close), with a high of $90.00 and a low of $46.00. Analyst consensus is Strong Buy, based on the latest ratings from 7 firms (6 buy, 1 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in XENE, 100% of them bullish and 0% bearish. In the past 30 days there were 1 dark pool print totaling $728K, the largest $728K.
Each firm's latest rating on XENE in the past 90 days
Average 12-month target
$65.43
▲ 68.7% upside
Based on 7 analysts who set a price target on XENE in the past 90 days. The average target is $65.43, with a high of $90.00 and a low of $46.00, compared with the last close of $38.78.
Low $46.00Avg $65.43High $90.00
Blue marker: last close $38.78
Highest target$90.00
Average target$65.43
Lowest target$46.00
Latest rating changes
GuggenheimAssumed coverage
Oct 6Buy$73
RBC CapitalTarget lowered
Sep 18Buy$81 → $70
WedbushMaintained
Sep 18Buy$55
Wells FargoMaintained
Sep 18Buy$64
Deutsche BankDowngrade
Sep 18Hold$46
Date
Firm
Action
Rating
Price target
Oct 6
Guggenheim
Assumed coverage
Buy
$73
Sep 18
RBC Capital
Target lowered
Buy
$81 → $70
Sep 18
Wedbush
Maintained
Buy
$55
Sep 18
Wells Fargo
Maintained
Buy
$64
Sep 18
Deutsche Bank
Downgrade
Hold
$46
Loading…
Technical Analysis
XENE · as of the Nov 17 close · updated after every close
Bounce inside a longer downtrend
The stock sits between its 20 and 50 day averages. It is 35% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 48). The nearest support is the 20 day average at $38.31, and the nearest resistance the Pivot at $38.83.
Short trendBullish
Long trendBearish
MomentumImproving
StretchNormal
VolatilityNormal, 3.8%/day
Key levels
$72.6652 week high+87.4%
$52.25200 day average+34.7%
$51.92100 day average+33.9%
$40.3050 day average+3.9%
$39.92Swing high (Oct 1)+2.9%
$39.42Pivot R1+1.7%
$38.83Pivot+0.1%
$38.78Last close
$38.3120 day average−1.2%
$38.18Pivot S1−1.5%
$37.15Swing low (Nov 6)−4.2%
$33.3852 week low−13.9%
Indicators
RSI (14)
47.72
Middle of its range
Neutral
MACD
0.16
Above its signal line
Bullish
Stochastic
57.3
Middle of its range
Neutral
ADX (14)
21.3
Weak trend
Williams %R
-59.9
Oversold below −80, overbought above −20
Neutral
CCI (20)
23.4
Oversold below −100, overbought above 100
Neutral
Rate of change
+1.4%
Change over 10 sessions
Bullish
ATR (14)
$1.49
Typical daily range, 3.8% of price
MA 10Below
MA 20Above
MA 50Below
MA 100Below
MA 200Below
Falling, nearing oversold
Short trendBearish
Long trendNot enough history
MomentumWeak
StretchNear oversold
VolatilityHigh, 11.4%/day
Key levels
$72.6652 week high+87.4%
$52.25200 day average+34.7%
$51.92100 day average+33.9%
$40.3050 day average+3.9%
$39.92Swing high (Oct 1)+2.9%
$39.42Pivot R1+1.7%
$38.83Pivot+0.1%
$38.78Last close
$38.3120 day average−1.2%
$38.18Pivot S1−1.5%
$37.15Swing low (Nov 6)−4.2%
$33.3852 week low−13.9%
Indicators
RSI (14)
37.09
Weak, oversold below 30
Neutral
MACD
-4.71
Below its signal line
Bearish
Stochastic
18.9
Near the bottom of its range
Oversold
ADX (14)
33.6
Trending down
Williams %R
-82.9
Oversold below −80, overbought above −20
Oversold
CCI (20)
-62.1
Oversold below −100, overbought above 100
Neutral
Rate of change
−33.9%
Change over 10 sessions
Bearish
ATR (14)
$4.43
Typical daily range, 11.4% of price
MA 10Above
MA 20Below
MA 50Below
MA 100Below
MA 200–
What happened before, for XENE
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how XENE did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow XENE usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How XENE has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether XENE is in one of them and how their past XENE trades turned out.
Xenon Pharmaceuticals is a biopharmaceutical company based in Burnaby, Canada, that focuses on drugs for neurological and psychiatric conditions. Its lead investigational medicine, azetukalner, is in late-stage trials for epilepsy, major depressive disorder and bipolar depression. The company also has earlier-stage programs aimed at pain and other conditions. Its intended customers are patients with these disorders, and it may commercialize its candidates alone or with partners.